Transmission of HIV-1 drug-resistant variants: Prevalence and effect on treatment outcome

Clinical Infectious Diseases

Volumn 50, Issue 4, 2010, Pages 566-573

  Jakobsen, Martin R ^a,c   Tolstrup, Martin ^a   Sogaard, Ole S ^a   Jorgensen, Louise B ^b   Gorry, Paul R ^c,d   Laursen, Alex ^a   Østergaard, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; DENMARK; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; PREVALENCE; PROSPECTIVE STUDIES; PROVIRUSES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 75749155415     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650001     Document Type: Article

References (33)

1. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
2. Holmberg SD, Hamburger ME, Moorman AC, Wood KC, Palella FJ Jr. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. Clin Infect Dis 2003; 37; 702-707.
3. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era; changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43; 27-34. (Pubitemid 44306484)
4. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study an observational study. Lancet 2003; 362: 22-29. (Pubitemid 36835816)
5. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59: 1047-1056. (Pubitemid 47073314)
6. Fox J, Hill S, Kaye S, et al. Prevalence of primary genotypic resistance in a UK centre: comparison of primary HIV-1 and newly diagnosed treatment-naive individuals. AIDS 2007; 21: 237-239. (Pubitemid 46036933)
7. Babic DZ, Zelnikar M, Seme K, et al. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res 2006; 118: 156-163.
8. Poggensee G, Kucherer C, Werning J, et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success: data from the German HIV-I Seroconverter Study. HIV Med 2007; 8: 511-519. (Pubitemid 47616830)
9. Truong HM, Grant RM, McFarland W, et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 2006; 20: 2193-2197. (Pubitemid 44684710)
10. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapynaive HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007; 8: 1-8. (Pubitemid 46542904)
11. Jorgensen LB, Gerstoft J, Mathiesen LR, et al. Low prevalence of transmitted HIV-1 drug resistance in newly diagnosed HIV-1 patients in Denmark from 2000-2004. In: Program and abstracts of the Monte Carlo 4th European HIV Drug Resistance Workshop. 2006. Abstract 22.
12. Jorgensen LB. Epidemiology of transmitted drug resistance in newly diagnosed HIV-1 individuals in Denmark from 2001 to 2007. In: Program and abstract of the 7th European HIV Drug Resistance Workshop. Stockholm, Sweden. 2009.
13. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-966. (Pubitemid 41266791)
14. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-635.
15. SchuurmanR,DemeterL,ReichelderferP,TijnagelJ,deGrootT,BoucherC.WorldwideevaluationofDNAsequencingapproachesforofdrugresistancemutationsinthehumanimmunodeficiencyvirustype1reversetranscriptase.JClinMicrobiol1999;37:2291-2296.(Pubitemid29277794)
16. Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002; 18: 243-248. (Pubitemid 34253141)
17. Turriziani O, Bucci M, Stano A, et al. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007; 44: 518-524. (Pubitemid 46594894)
18. Parisi SG, Boldrin C, Crudani M, et al. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol 2007; 45: 1783-1788. (Pubitemid 46933907)
19. Bon I, Gibellini D, Borderi M, et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007; 38: 313-320. (Pubitemid 46413996)
20. Kearney M, Palmer S, Maldarelli F, et al. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 2008; 22: 497-501. (Pubitemid 351317291)
21. Peuchant O, Thiebaut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008; 22: 1417-1423.
22. Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatmentnaive and -adherent patients. Clin Infect Dis 2009; 48: 239-247.
23. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5: el58.
24. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-na-ive patients significantly impact treatment outcomes. J Infect Dis 2009; 199: 693-701.
25. Jakobsen MR, Aggerholm A, Jorgensen LB, Laursen A, Ostergaard L. Pre-screening HIV-1 reverse transcriptase mutations in subtype B patients using a novel multiplex primer extension assay. Curr HIV Res 2009; 7: 398-409.
26. Jakobsen MR, Tolstrup M, Bertelsen L, et al. Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+ T cell proviral DNA. J Clin Virol 2007; 39: 215-221. (Pubitemid 46907726)
27. Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38: 37-42. (Pubitemid 40094116)
28. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188: 1433-1443. (Pubitemid 37523928)
29. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV N Engl J Med 2002; 347: 385-394.
30. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 2004; 30: 1-10.
31. GrantRM,HechtFM,WarmerdamM,etal.TimetrendsinprimaryHIV-1drugresistanceamongrecentlyinfectedpersons.JAMA2002;288:181-188.(Pubitemid34755278)
32. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3: e356.
33. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82: 5510-5518. (Pubitemid 351705258)